Benitec Biopharma Inc. reported full-year financial results for the fiscal year ended June 30, 2026, alongside an operational update on its lead candidate BB-301. The company incurred a net loss of $45.5 million, or $0.98 per share, compared to a $37.9 million loss in the prior year, driven by increased research and development expenses of $23.4 million and general and administrative costs of $27.8 million. As of June 30, 2026, Benitec held approximately $180 million in cash. Clinically, all six Cohort 1 patients completed the 12-month follow-up period for BB-301, while Cohort 2 is fully enrolled with three safely treated patients. The company held a Type C meeting with the FDA to discuss pivotal study design and anticipates initiating the pivotal trial in mid-2027. Benitec Biopharma Inc. operates as a clinical-stage biotechnology company developing disease-modifying genetic medicines using its proprietary ddRNAi platform.